- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02488044
A Phase 1/2 Study of AEB1102 in Patients With Arginase 1 Deficiency
A Phase 1/2 Open-label Study in Patients With Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102. This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase 1 deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing. A data safety monitoring board (DSMB) will provide independent review of study safety data and recommend whether the sponsor should continue the study as planned, modify the study protocol, or discontinue the study.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford University School of Medicine
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32611
- University of Florida
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Children's Hospital of Michigan
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- UTSW
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Seattle Children's Hospital
-
-
-
-
-
Porto, Portugal
- Centro Hospitalar S. Joao
-
-
-
-
-
London, Reino Unido
- Great Ormond Street Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female ≥ 2 years
- Documented diagnosis of Arginase 1 deficiency
- Adequate organ function as defined by laboratory assessment
- If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
- If a sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
- Patient or legal guardian is able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification) prior to any screening procedures
Exclusion Criteria:
- Transfusion of ≥ 2 units of RBCs within 60 days
- Active infection requiring systemic treatment
- Known infection with HIV, Hep B or Hep C
- Unstable hyperammonemia requiring hospitalization within 14 days
- Has a history of hypersensitivity to PEG or any other component of the AEB1102 (Co-ArgI-PEG) formulation
- If female, is lactating or breast feeding
PART 2 INCLUSION CRITERION:
1. Did not experience any safety or tolerability event in Part 1 which would preclude continued participation and dosing of AEB1102
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: AEB1102
AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks. Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy. |
modified human arginase I
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Adverse Events Related to ECGs
Prazo: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing ECG results was through assessing AEs related to ECGs. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
|
Number of Participants With Adverse Events Related to Clinical Laboratory Results
Prazo: Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
The primary means of assessing clinical laboratory results was through assessing AEs related to clinical laboratory results. Laboratory studies included hematology, chemistry, urinalysis, and coagulatio. |
Weekly throughout the study, up to 14 weeks (Part 2 week 8)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetic Profile of IV AEB1102: Time of the Maximum Observed Concentration (Tmax)
Prazo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Through the Time of the Last Measurable Concentration (AUC0-t)
Prazo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Maximum Observed Concentration (Cmax)
Prazo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Apparent Terminal Elimination Half-life (T1/2)
Prazo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Area Under the Curve Extrapolated to Infinity (AUC0-∞)
Prazo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Serum Clearance (CL)
Prazo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Pharmacokinetic Profile of IV AEB1102: Volume of Distribution (Vss)
Prazo: After 8 weeks of repeat-dosing (Part 2)
|
Individualized doses (0.015-0.2 mg/kg IV) were administered. Pharmacokinetic parameters were calculated using concentration-time data obtained following the administered dose and summarized descriptively. |
After 8 weeks of repeat-dosing (Part 2)
|
|
Plasma Arginine Concentrations After AEB1102 IV
Prazo: 168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
Plasma arginine concentration post dose AEB1102 IV |
168 hrs post dose, Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Guanidinoacetic Acid (GAA)
Prazo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: α-keto-δ-guanidinovaleric Acid (GVA)
Prazo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: Argininic Acid (ARGA)
Prazo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
|
Effect of AEB1102 on Plasma Guanidino Compounds: N-α-acetyl-L-arginine (NAA)
Prazo: Part 2: Change from Baseline to 8 weeks
|
Change from baseline to 8 weeks of reapeat-dosing (Part 2) in plasma concentration |
Part 2: Change from Baseline to 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB
Publicações e links úteis
Publicações Gerais
- Diaz GA, Schulze A, McNutt MC, Leao-Teles E, Merritt JL 2nd, Enns GM, Batzios S, Bannick A, Zori RT, Sloan LS, Potts SL, Bubb G, Quinn AG. Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency. J Inherit Metab Dis. 2021 Jul;44(4):847-856. doi: 10.1002/jimd.12343. Epub 2021 Jan 26.
- Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. Mol Genet Metab. 2005 Mar;84(3):243-51. doi: 10.1016/j.ymgme.2004.11.004. Epub 2004 Dec 19.
- Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011 Jun;4(3):138-46. doi: 10.1593/tlo.10265. Epub 2011 Jun 1.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Doenças Cerebrais Metabólicas Inatas
- Doenças Cerebrais Metabólicas
- Metabolismo de Aminoácidos, Erros Inatos
- Distúrbios Inatos do Ciclo da Uréia
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças Nutricionais e Metabólicas
- Hiperargininemia
Outros números de identificação do estudo
- CAEB1102-101A
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .